Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from ...

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...

The latest announcement is out from Collegium Pharmaceutical ( (COLL) ). Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with ...

Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue Expected to be in ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report)’s stock price reached a new 52-week low during trading on Monday . The stock traded as low as $28.50 and last traded at $28.56, with a ...

In a challenging market environment, Collegium Pharmaceutical Inc. (NASDAQ:COLL) stock has touched a 52-week low, dipping to $28.46. Despite the recent decline, InvestingPro analysis reveals ...

Short interest in Collegium Pharmaceutical Inc (NASDAQ:COLL) decreased during the last reporting period, falling from 6.29M to 6.11M. This put 23.48% of the company's publicly available shares short.

This page features the latest news about the Collegium Pharmaceutical stock. Collegium stock hits 52-week low at $28.46 amid market challenges In a challenging market environment, Collegium ...

Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) shares shot up 2.8% during mid-day trading on Wednesday . The ...

GET MORE AI-GENERATED SIGNALS: January 03, 2025, 16:08 pm ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...